Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany

Table 2

Anticancer drugs used in the 1st-line treatment of patients advanced or metastatic esophagogastric adenocarcinoma () documented in Therapiemonitor 2006–2013. Indicated is the number of patients receiving the respective drugs in the respective years and/or quarters.

	Total number of patients; 2006–2009; (%)	Total number of patients; 2010; (%)	Total number of patients; II.-III. quarter 2011; (%)	Total number of patients; III. quarter 2012; (%)	Total number of patients; III. quarter 2013; (%)
Cisplatin	538 (51.1)	370 (49.1)	112 (35.7)	103 (31.7)	114 (31.9)
Oxaliplatin	251 (23.8)	286 (37.9)	161 (51.3)	170 (52.3)	188 (52.7)
Capecitabine	133 (12.6)	177 (23.5)	77 (24.5)	75 (23.1)	69 (19.3)
Docetaxel	216 (20.5)	193 (25.6)	103 (32.8)	112 (34.5)	128 (35.9)
Paclitaxel	6 (0.6)	2 (0.3)	1 (0.3)	—	2 (0.6)
Irinotecan	92 (8.7)	31 (4.1)	12 (3.8)	20 (6.2)	13 (3.6)
Epirubicin	107 (10.2)	186 (24.7)	60 (19.1)	42 (12.9)	25 (7.0)
Mitomycin C	12 (1.1)	5 (0.7)	—	—	—
Etoposide	45 (4.3)	7 (0.9)	3 (1.0)	2 (0.6)	3 (0.8)
Evaluable patients ()	1053	754	314	325	357